IgG subclasses determine pathways of anaphylaxis in mice by Beutier, Héloïse et al.
HAL Id: pasteur-01388338
https://hal-pasteur.archives-ouvertes.fr/pasteur-01388338
Submitted on 26 Oct 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Copyright
IgG subclasses determine pathways of anaphylaxis in
mice
Héloïse Beutier, Caitlin M. Gillis, Bruno Iannascoli, Ophélie Godon, Patrick
England, Riccardo Sibilano, Laurent L. Reber, Stephen J. Galli, Mark S.
Cragg, Nico van Rooijen, et al.
To cite this version:
Héloïse Beutier, Caitlin M. Gillis, Bruno Iannascoli, Ophélie Godon, Patrick England, et al.. IgG
subclasses determine pathways of anaphylaxis in mice. Journal of Allergy and Clinical Immunology,
Elsevier, 2016, In press, ￿10.1016/j.jaci.2016.03.028￿. ￿pasteur-01388338￿
                                                                                                                                       Beutier 
 
 
1 
IgG subclasses determine pathways of anaphylaxis in mice 1 
 2 
 3 
 4 
Héloïse Beutier, PharmD1,2,3, Caitlin M. Gillis, B.Sci. 1,2,3, Bruno Iannascoli, [no 5 
degree]1,2, Ophélie Godon, M.Sc.1,2, Patrick England, PhD4, Riccardo Sibilano, 6 
PhD5,6, Laurent L. Reber, PhD1,2, Stephen J. Galli, MD5,6, Mark S. Cragg, PhD7, 7 
Nico Van Rooijen, PhD8, David A. Mancardi, PhD1,2, Pierre Bruhns, PhD1,2,* and 8 
Friederike Jönsson, PhD1,2,* 9 
 10 
 11 
Authors’ affiliations 12 
1Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, 13 
Paris, France; 14 
2INSERM, U1222, Paris, France; 15 
3Université Pierre et Marie Curie, Paris, France; 16 
4Institut Pasteur, Plate-Forme de Biophysique Moléculaire, Centre d'Innovation et Recherche 17 
Technologique (CiTech), CNRS-UMR3528, Paris, France; 18 
5Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.  19 
6Sean N. Parker Center for Allergy Research, Stanford University School of Medicine, Stanford, 20 
CA, USA.  21 
7Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of 22 
Medicine, Southampton General Hospital, Southampton, UK 23 
8Department of Molecular Cell Biology, VU Medical Center, Amsterdam, The Netherlands; 24 
*co-senior authorship. 25 
 26 
 27 
 28 
                                                                                                                                       Beutier 
 
 
2 
Sources of funding: none of the sources of funding have an interest in the subject matter or 29 
materials discussed in the submitted manuscript 30 
 31 
 32 
 33 
 34 
Correspondence to: Friederike Jönsson and Pierre Bruhns, Unit of Antibodies in Therapy and 35 
Pathology, Department of Immunology, Institut Pasteur, 25 rue du Docteur Roux, 75015 Paris, 36 
France. Phone: +33144389144 or +33145688629. E-mail: joensson@pasteur.fr; 37 
bruhns@pasteur.fr 38 
39 
                                                                                                                                       Beutier 
 
 
3 
ABSTRACT 40 
Background: Animal models have demonstrated that allergen-specific IgG confers sensitivity to 41 
systemic anaphylaxis that relies on IgG receptors (FcγRs). Mouse IgG2a and IgG2b bind 42 
activating FcγRI, FcγRIII and FcγRIV, and inhibitory FcγRIIB; mouse IgG1 binds only FcγRIII 43 
and FcγRIIB. Although these interactions are of strikingly different affinities, these three IgG 44 
subclasses have been shown to enable induction of systemic anaphylaxis. 45 
Objective: Determine which pathways control the induction of IgG1-, IgG2a- and IgG2b-passive 46 
systemic anaphylaxis. 47 
Methods: Mice were sensitized with IgG1, IgG2a or IgG2b anti-TNP mAbs and challenged with 48 
TNP-BSA intravenously to induce systemic anaphylaxis that was monitored using rectal 49 
temperature. Anaphylaxis was evaluated in mice deficient for FcγRs, injected with mediator 50 
antagonists or in which basophils, monocyte/macrophages or neutrophils had been depleted. The 51 
expression of FcγRs was evaluated on these cells before and after anaphylaxis. 52 
Results: Activating FcγRIII is the receptor primarily responsible for all three models of 53 
anaphylaxis, and subsequent down regulation of this receptor was observed. These models 54 
differentially relied on histamine release and on the contribution of mast cells, basophils, 55 
macrophages and neutrophils. Strikingly, basophil contribution and histamine predominance in 56 
IgG1- and IgG2b-mediated anaphylaxis correlated with the ability of inhibitory FcγRIIB to 57 
negatively regulate these models of anaphylaxis. 58 
Conclusion: We propose that the differential expression of inhibitory FcγRIIB on myeloid cells 59 
and its differential binding of IgG subclasses controls the contributions of mast cells, basophils, 60 
neutrophils and macrophages to IgG subclass-dependent anaphylaxis. Collectively, our results 61 
unravel novel complexities in the involvement and regulation of cell populations in IgG-mediated 62 
reactions in vivo.  63 
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CLINICAL IMPLICATIONS 64 
Anaphylactic pathways induced by different IgG subclasses in mice vary in terms of 65 
contributions by different cell types, mediators and antibody receptors. These results may help in 66 
the design of efforts to understand and treat IgG-mediated anaphylaxis in humans, e.g., as seen 67 
following intravenous IgG or administration of therapeutic IgG antibodies. 68 
 69 
CAPSULE SUMMARY 70 
 71 
Antibodies of the IgG class can contribute to anaphylaxis. This report reveals pathways induced 72 
by each IgG subclass in experimental anaphylaxis, demonstrating varying contributions of cells, 73 
mediators and antibody receptors. 74 
 75 
 76 
KEY WORDS 77 
 78 
Anaphylaxis; IgG; mouse model; basophil; neutrophil; monocyte; macrophage; FcγR; Platelet-79 
activating Factor; Histamine. 80 
  81 
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ABBREVIATIONS USED 82 
 83 
FcγR: IgG Fc receptor 84 
PAF: Platelet-activating factor 85 
KA: Affinity constant 86 
WT: C57Bl/6 Wild-type 87 
PSA: Passive systemic anaphylaxis 88 
TNP: Trinitrophenyl 89 
BSA: Bovine serum albumin 90 
mAb: Monoclonal antibody 91 
PBS: Phosphate Buffered Saline 92 
Gfi1: Growth Factor Independence-1 93 
GeoMean: Geometric Mean 94 
SEM: Standard error of the mean 95 
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INTRODUCTION 97 
 98 
 Anaphylaxis is a hyperacute allergic reaction that occurs with increasing incidence in the 99 
population and can be of fatal consequence. Symptoms include skin rashes, hypotension, 100 
hypothermia, abdominal pain, bronchospasm and heart and lung failure that may lead to asphyxia 101 
and sometimes death1. The main treatment remains epinephrine (adrenaline) injection to restore 102 
heart and lung function. Since anaphylaxis represents an emergency situation, few clinical studies 103 
have been possible to address the mechanisms leading to anaphylaxis in patients. Experimental 104 
models of anaphylaxis identified mechanisms involving allergen-specific antibodies that trigger 105 
activating antibody receptors on myeloid cells, leading to the release of mediators. These 106 
mediators can, by themselves, recapitulate the symptoms of anaphylaxis as observed in humans2, 107 
3. 108 
 The “classical” mechanism of anaphylaxis states that allergen-specific IgE binds the 109 
activating IgE receptor FcεRI on mast cells, which upon allergen encounter become activated and 110 
release histamine, among other mediators. Notably, histamine injection suffices to induce the 111 
signs of anaphylaxis in animal models4. In many cases, detectable allergen-specific IgE and 112 
elevated histamine levels do not accompany anaphylaxis in humans (discussed in 5), leading to 113 
the notion that “atypical” or “alternate” mechanisms of induction could explain these cases. One 114 
of these atypical/alternate models proposes a similar cascade of events, but instead based on 115 
allergen-specific IgG binding to allergen, forming IgG-allergen immune complexes that trigger 116 
activating IgG receptors (FcγRs) expressed on myeloid cells (i.e. macrophages, basophils and/or 117 
neutrophils), which in turn release Platelet-Activating Factor (PAF)2,3. Importantly, PAF 118 
injection suffices to induce the signs of anaphylaxis in animal models 6. IgG-induced anaphylaxis 119 
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can be elicited by intravenous injection of allergen-specific IgG followed by allergen 120 
administration, and is termed IgG-induced passive systemic anaphylaxis (PSA). 121 
 IgG receptors in the mouse comprise four “classical“ IgG receptors termed FcγRs, but 122 
also the neonatal IgG receptor (FcRn) and the intracellular FcR tripartite motif-containing protein 123 
21 (TRIM21)7, 8. Whereas FcRn and TRIM21 both participate in the intracellular routing of IgG, 124 
and FcRn in protection from catabolism and distribution to tissues9, FcγRs control cell activation 125 
in the presence of immune complexes. FcγRs in mice are subdivided into i) activating FcγRs, i.e. 126 
FcγRI, FcγRIII and FcγRIV, that lead to cell activation upon immune complex binding, and ii) an 127 
inhibitory FcγR, i.e. FcγRIIB, that inhibits cell activation when co-engaged by an immune 128 
complex with an activating FcγR co-expressed on the same cell10. Inhibition of cell activation by 129 
FcγRIIB thus requires that the immune complex contains IgG that are bound both by the 130 
activating and by the inhibitory FcγR. 131 
 Four IgG subclasses exist in mice, IgG1, IgG2a, IgG2b and IgG3. Among those, only 132 
IgG2a and IgG2b bind to all FcγRs, whereas IgG1 binds only to FcγRIIB and FcγRIII. It remains 133 
under debate whether IgG3 binds to FcγRs, particularly FcγRI11, 12. The affinities of these FcγRs 134 
towards IgG subclasses are strikingly different (Table 1) leading to the notion of “high-affinity” 135 
receptors that retain monomeric IgG and “low-affinity” receptors that do not8. The avidity of 136 
IgG-immune complexes, however, enables both types of receptors to retain IgG-immune 137 
complexes, leading to receptor clustering, intracellular signaling events and, eventually, to cell 138 
activation. FcγRI is a high-affinity receptor for IgG2a13, and FcγRIV is a high-affinity receptor 139 
for IgG2a and IgG2b14. All other FcγR-IgG interactions are of low affinity (reviewed in 7). 140 
 Three out of the four IgG subclasses in the mouse, i.e. IgG1, IgG2a and IgG2b, have been 141 
reported to enable the induction of systemic anaphylaxis, inducing mild to severe hypothermia5, 142 
15, 16. This is rather surprising for IgG1, considering that inhibitory FcγRIIB binds IgG1 with a 143 
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10-fold higher affinity (KA=3.3x106 M-1) than activating FcγRIII (KA=3.1x105 M-1)17 (Table 1), 144 
implying that inhibition should dominate over activation. WT mice, indeed, develop a very mild 145 
anaphylactic reaction during IgG1-PSA compared to FcγRIIB-/- mice18, indicating that inhibition 146 
by FcγRIIB occurs in WT mice during IgG1-PSA, reducing, but not protecting from, 147 
anaphylaxis. IgG1-PSA has been reported to rely on basophils19 that co-express FcγRIIB and 148 
FcγRIII20. In this apparently simple situation, only one activating receptor and one inhibitory 149 
receptor are engaged on a single cell type that, once activated, produces an anaphylactogenic 150 
mediator, like PAF19. 151 
 IgG2a and IgG2b, however, bind three activating FcγRs and inhibitory FcγRIIB with 152 
different affinities ranging over 2 logs. In particular, the affinity of FcγRIIB for IgG2a is 153 
significantly lower than for IgG2b, whereas activating IgG receptors FcγRIII and FcγRIV bind 154 
IgG2a and IgG2b with similar affinities, respectively (Table 1). Notably, FcγRIV is not expressed 155 
on basophils, but on monocytes/macrophages and neutrophils21 that have both been reported to 156 
contribute to experimental anaphylaxis16, 22-24. In addition, mice expressing only FcγRIV can 157 
develop IgG-PSA16. Together with expression and binding data, one would therefore hypothesize 158 
that FcγRIV contributes predominantly to IgG2a- and IgG2b-PSA. In this work, we present 159 
evidence contrary to this hypothesis, and reveal which activating FcγR on which cell type(s) 160 
releasing which mediator(s) are responsible for IgG2a-PSA and IgG2b-PSA, and the differential 161 
regulation of these models of anaphylaxis by FcγRIIB. Our results unravel a complex balance 162 
determined by FcγR expression patterns, inhibition potential by FcγRIIB and respective affinities 163 
of activating and inhibitory FcγRs for IgG subclasses that, altogether, regulate the contribution of 164 
cells and anaphylactogenic mediators to a given model of IgG-induced anaphylaxis. 165 
  166 
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METHODS 167 
Mice. Female C57Bl/6J mice (herein referred to as “WT”) were purchased from Charles River, 168 
female Balb/cJRj mice from Janvier Labs, FcγRIIB-/- (MGI:1857166), FcγRIII-/- mice (MGI: 169 
3620982) and Rosa26-YFP mice from Jackson Laboratories. FcγRI-/- mice (MGI: 3664782) were 170 
provided by J. Leusen (University Medical Center, Utrecht, The Netherlands), FcγRIV-/- mice 171 
(MGI: 5428684) by J.V. Ravetch (The Rockefeller University, New York, NY, USA), Gfi1-/- 172 
mice by T. Moroy (Montreal University, Montreal, QC, Canada) and MRP8-cre mice by Clifford 173 
Lowell (University of California at San Francisco, CA, USA). MRP8-cre and Rosa26-YFP mice 174 
were intercrossed to generate MRP8-cre; Rosa26-YFP mice. Cpa3-Cre; Mcl-1fl/fl mice25 175 
(backcrossed for at least 9 generations on a C57Bl/6J background) were kept in the Stanford 176 
University animal facility. All mouse protocols were approved by the Animal Ethics committee 177 
CETEA (Institut Pasteur, Paris, France) registered under #C2EA-89, and the Institutional Animal 178 
Care and Use Committee of Stanford University. 179 
 180 
Antibodies and reagents. PBS- and clodronate-liposomes were prepared as previously 181 
described26. TNP(21-31)-BSA was obtained from Santa Cruz, ABT-491 from Sigma-Aldrich; 182 
cetirizine DiHCl from Selleck Chemicals; anti-mouse FcγRIII (275003) from R&D Systems; rat 183 
IgG2b isotype control (LTF-2) from Bio X Cell. Purified anti-CD200R3 (Ba103) was provided 184 
by H. Karasuyama (Tokyo Medical and Dental University Graduate School, Tokyo, Japan). The 185 
hybridoma producing mAbs anti-mouse FcγRIV (9E9) was provided by J.V. Ravetch 186 
(Rockefeller University, New York, New York, USA), anti-Ly6G (NIMP-R14) by C. Leclerc 187 
(Institut Pasteur, Paris, France), IgG1 anti-TNP (TIB-191) by D. Voehringer 188 
(Universitätsklinikum, Erlangen, Germany), IgG2a anti-TNP (Hy1.2) by Shozo Izui (University 189 
of Geneva, Geneva, Switzerland) and IgG2b anti-TNP (GORK) by B. Heyman (Uppsala 190 
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Universitet, Uppsala, Sweden): corresponding antibodies were purified as described16. Purified 191 
mouse IgE anti-TNP was purchased from BD Pharmingen. MAb 9E9 was coupled to FITC using 192 
the PierceTM FITC Antibody labeling kit (Life Technologies). The antibodies used for flow 193 
cytometry staining of c-Kit (clone 2B8), CD49b (clone DX5), IgE (clone R35-72), CD11b (clone 194 
M1/70), F4/80 (clone 6F12), CD115 (clone T38-320), Ly6G (clone 1A8) and Ly6C (clone AL-195 
21) were purchased from BD Pharmingen; CD45 (clone 30F11) and Gr1 (clone RB6-8C5) were 196 
purchased from Miltenyi Biotec. FcγRIIB was detected using FITC-coupled mAb AT130-2 197 
mIgG1 N297A27. 198 
 199 
Passive Systemic Anaphylaxis. IgG-induced PSA: IgG1, IgG2a or IgG2b anti-TNP antibodies 200 
were administered intravenously at a dose of 500 µg, if not otherwise indicated, in 200 µL 201 
physiological saline, followed by an intravenous challenge with 200 µg of the antigen (TNP-202 
BSA) in physiological saline 16 hours later. IgE-induced PSA: IgE anti-TNP antibodies were 203 
administered intravenously at a dose of 50 µg in 200 µL physiological saline followed by an 204 
intravenous challenge with 500 µg of TNP-BSA in physiological saline 24 hours later. The body 205 
temperature of mice was monitored using a digital thermometer with rectal probe (YSI). 206 
 207 
In vivo blocking and cellular depletion. 300 µg/mouse of PBS- or clodronate-liposomes, 300 208 
µg/mouse of rat IgG2b isotype control or anti-Ly6G, and 30 µg/mouse of anti-CD200R3 mAbs 209 
were injected i.v. 24 hours before challenge. Specificity of cell depletion was evaluated using 210 
flow cytometry on blood, bone marrow, spleen and peritoneum taken from naïve WT mice 24 211 
hours after injection of the depleting antibody or clodronate-liposomes (Examples are shown in 212 
Supplemental Figures 1 & 2). 25 µg/mouse of ABT-491 or 300 µg/mouse of cetirizine were 213 
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injected intravenously 20 minutes or intraperitoneally 30 minutes before challenge, respectively. 214 
200 µg/mouse of anti-FcγRIV mAb were injected intravenously 30 minutes before challenge. 215 
 216 
Flow cytometry analysis. Freshly isolated cells were stained with indicated fluorescently labeled 217 
mAbs for 30 minutes at 4°C. Cell populations were defined as follows: neutrophils 218 
(CD45+/CD11b+/Ly6Ghi/Ly6Cint), monocytes (CD45+/CD11b+/Ly6Glo/Ly6Clo or hi), basophils 219 
(CD45int/DX5+/IgE+); spleen macrophages (CD45+/CD11b+/Gr-1lo/CD115+/F4/80hi); peritoneal 220 
macrophages (CD45+/CD11b+/F4/80+); peritoneal mast cells (CD45+/c-Kit+/IgE+). Expression of 221 
FcγR on indicated cell population is represented as Δ Geomean between specific and isotype 222 
control staining. NB: In Figure 5: 1 or 0.5 mg IgG2b was injected to assess expression on 223 
neutrophils/monocytes or basophils, respectively. 224 
 225 
Surface plasmon resonance analysis. Experiments were performed at 25°C using a ProteOn 226 
XPR36 real-time SPR biosensor (BioRad). Anti-TNP antibodies were immobilized covalently 227 
through amine coupling on the surface of a GLC chip. TNP-BSA was then injected on the chip at 228 
a flow rate of 25 µl.min-1, with contact and dissociation time of 8 minutes each. Binding 229 
responses were recorded in real time as resonance units (RU; 1 RU ≈ 1 pg/mm2). Background 230 
signals were subtracted, and binding rates (kon and koff) and equilibrium constants (Kd) were 231 
determined using the Biaevaluation software (GE Healthcare). 232 
 233 
ELISAs. After the induction of IgG1-, IgG2a-, IgG2b- or IgE-induced PSA, plasma and serum 234 
were collected at 5 minutes and 3 hours later to determine the histamine and mMCP-1 content, 235 
respectively. Histamine and mMCP-1 concentration were determined using commercially 236 
available ELISA kits (Beckman Coulter; eBioscience) following the manufacturer’s instructions. 237 
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Relative binding affinity of IgG1, IgG2a and IgG2b anti-TNP antibodies to TNP-BSA was 238 
determined by ELISA. Briefly, TNP-BSA-coated plates were incubated with dilutions of IgG1, 239 
IgG2a or IgG2b anti-TNP antibodies. After washing, bound anti-TNP IgG were revealed using 240 
the same HRP-coupled anti-mouse IgG and SIGMAFAST OPD solution.  241 
 242 
Mast cell histology. Mouse back skin biopsies were collected 24 hours after the induction of 243 
specific cell depletion and mouse ear skin biopsies were collected 30 minutes after IgE, IgG1, 244 
IgG2a or IgG2b-induced PSA, and embedded in paraffin prior to sectioning. Mast cells in 245 
toluidine blue-stained biopsies were counted visually in at least 15 FOV/mouse and > 6 mice per 246 
treatment (Supplemental Figure 1I).  247 
 248 
Statistics. Data were analyzed using one-way or two-way ANOVA with Tukey’s post-test. A p-249 
value less than .05 was considered significant: (*p < .05; **p < .01; ***p < .001; ****p < .0001). 250 
If not stated otherwise, data are represented as mean +/- SEM. 251 
 252 
  253 
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RESULTS 254 
 255 
FcγRIII dominates anaphylaxis induced by IgG subclasses 256 
 Passive systemic anaphylaxis was induced by an intravenous injection of one of the 257 
different anti-TNP IgG isotypes (IgG1, IgG2a, IgG2b) followed by an intravenous challenge with 258 
TNP-BSA 16 h later. This protocol induces a transient decrease in body temperature that is most 259 
pronounced between 30 and 40 minutes. As reported previously3, 16, 19, 22, 28, all three IgG isotypes 260 
were capable of inducing anaphylaxis in WT mice (Figure 1A-C). In these experimental 261 
conditions IgG1-PSA triggered a maximum temperature loss of ≈2°C, IgG2a-PSA of ≈4°C and 262 
IgG2b-PSA of ≈3°C in WT mice. Using single FcγR-knockout mice we evaluated the 263 
contribution of each of the four mouse FcγRs to these anaphylaxis models. The absence of either 264 
FcγRIV (with the exception of a single time point in IgG2b-PSA) or FcγRI had no significant 265 
impact on IgG-PSA-induced hypothermia, regardless of the subclass of IgG antibodies used to 266 
induce anaphylaxis (Figure 1A-C). The lack of FcγRIII, however, protected mice from 267 
anaphylaxis in all models. Mice lacking the inhibitory receptor FcγRIIB had a significantly more 268 
severe temperature drop than WT mice in both IgG1- and IgG2b-PSA, but showed no significant 269 
difference in the severity of IgG2a-PSA (Figure 1A-C). Even though the three anti-TNP IgG 270 
mAbs used are not switch variants of a unique anti-TNP antibody, they show comparable binding 271 
to TNP-BSA by ELISA, similar affinity (nanomolar range) and dissociation rates (koff) by surface 272 
plasmon resonance analysis, particularly the IgG2a and IgG2b anti-TNP antibodies 273 
(Supplemental Figures 3A, B & C). Of note, untreated FcγR-deficient mice presented modest 274 
variations in FcγR expression levels (Supplemental Figure 5) and leukocyte representation among 275 
blood cells compared to WT mice (Supplemental Figure 6). In particular, a mild lymphopenia in 276 
FcγRIV-/- mice and in FcγRIIB-/- mice (the latter also have a tendency to express higher levels of 277 
                                                                                                                                       Beutier 
 
 
14 
FcγRIII and FcγRIV); and a mild eosinophilia in FcγRIII-/- mice, that also express significantly 278 
more FcγRIIB on neutrophils and Ly6Chi monocytes. Together, we think that these variations do 279 
not explain the drastic phenotypes observed for PSA in FcγRIIB-/- and FcγRIII-/- mice compared 280 
to WT mice. Thus, these data demonstrate that FcγRIII predominates in the induction of IgG1-, 281 
IgG2a- and IgG2b-PSA, and that FcγRIIB specifically dampens anaphylaxis severity in IgG1- 282 
and IgG2b-PSA. 283 
 284 
Basophils, mast cells, monocytes/macrophages and neutrophils contribute differentially to 285 
IgG isotype-dependent anaphylaxis models 286 
 FcγRIII is expressed by all myeloid cells7, 20 and to a lesser extent by NK cells29. One may 287 
therefore anticipate that IgG immune complexes formed in vivo as a consequence of TNP-BSA 288 
injection in anti-TNP sensitized mice would therefore engage FcγRIII on these cells, leading to 289 
cell activation and possibly contributing to anaphylaxis. Basophils, mast cells, neutrophils and 290 
monocyte/macrophages have indeed been reported to contribute to IgG-PSA16, 19, 22, 15, however 291 
the respective contribution of each of these different cell types remains debated2, 28. To 292 
investigate which cell types contribute to PSA induced by different IgG subclasses, we depleted 293 
basophils (anti-CD200R3 mAb), monocytes/macrophages (clodronate-filled liposomes) or 294 
neutrophils (anti-Ly6G) prior to anaphylaxis induction or evaluated anaphylaxis induction in 295 
transgenic mice deficient in certain cell populations.  296 
 Of note, the relatively mild temperature loss in IgG1-PSA in WT mice (Supplemental 297 
Figure 4A), did not allow us to address reliably the contribution of either basophils or neutrophils 298 
to this model of anaphylaxis. We therefore restricted our analysis of the contribution of myeloid 299 
cell populations to IgG2a-PSA and IgG2b-PSA. Antibody-induced basophil depletion or 300 
genetically-induced mast cell and basophil deficiency (Supplemental Figure 2H, Cpa3-Cre; Mcl-301 
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1fl/fl mice25), did not affect IgG2a–PSA (Figure 2A&B), but significantly inhibited IgG2b-PSA 302 
(Figure 2F&G). Monocyte/macrophage depletion (Figure 2C&H) significantly inhibited both 303 
IgG2a- and IgG2b-PSA. The absence of neutrophils, either following antibody-mediated 304 
depletion (Figure 2D&I) or using neutropenic Gfi1-/- mice30 (Figure 2E&J), significantly 305 
inhibited both IgG2a- and IgG2b-PSA. Whereas monocytes/macrophages and neutrophils appear 306 
to contribute to both models of anaphylaxis, basophils and possibly mast cells therefore 307 
contribute specifically to IgG2b-PSA, but not to IgG2a-PSA. 308 
 309 
FcγRIII is down-regulated specifically on neutrophils following IgG2a PSA 310 
Khodoun et al proposed to use the reduced expression level of FcγRIII on mouse 311 
neutrophils as a marker to distinguish IgE- from IgG1-induced PSA, both of which required 312 
priming with an antigen-specific IgG1 and challenge with that antigen31. We therefore wondered 313 
if FcγRIII expression on neutrophils might also be a marker for IgG2a- and IgG2b-PSA. In 314 
addition, reduced expression of FcγR(s) following IgG-PSA may document that a particular cell 315 
population is activated following engagement of its FcγR(s) by IgG-immune complexes during 316 
anaphylaxis. This parameter may thus be used to discriminate cell populations contributing to 317 
anaphylaxis following direct activation by IgG-immune complexes from those contributing 318 
following activation by mediators liberated by IgG-immune complex-activated cells (e.g. 319 
histamine, PAF, leukotrienes and prostaglandins). 320 
Among mouse IgG receptors, only FcγRIIB, FcγRIII and FcγRIV are significantly 321 
expressed on circulating myeloid cells, but not FcγRI7, 32, 33. Of circulating monocyte populations, 322 
“classical” Ly6Chi monocytes are FcγRIIBmed, FcγRIIImed FcγRIV-, whereas “non-classical” 323 
Ly6Clo monocytes are FcγRIIBlo, FcγRIIIlo FcγRIVhi 34. We therefore determined the expression 324 
of FcγRIIB, FcγRIII and FcγRIV before and after IgG2a-PSA induction on neutrophils and 325 
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monocyte subsets. The expression of FcγRIII was down regulated on neutrophils, but not on 326 
Ly6Chi monocytes, during IgG2a-PSA (Figure 3A&D). The expression of FcγRIV was also down 327 
regulated on neutrophils, but not on Ly6Clo monocytes, during IgG2a-PSA (Figure 3B&D). This 328 
was unexpected considering that FcγRIV does not significantly contribute to this PSA model 329 
(Figure 1B). The expression of FcγRIIB, however, remained unchanged on Ly6Chi and Ly6Clo 330 
monocytes and neutrophils (Figure 3C&D), in agreement with the lack of contribution of this 331 
receptor to IgG2a-PSA (Figure 1B). Together these data suggest that neutrophils may directly be 332 
activated through FcγRIII by immune complexes formed during IgG2a-PSA. They also suggest 333 
that neutrophils, but not Ly6Clo monocytes, may be similarly activated through FcγRIV, even if 334 
no contribution of this receptor was identified in this model using FcγRIV-/- mice (Figure 1B).  335 
 336 
Elevated IgG2 antibody doses reveal FcγRIV contribution to IgG2a-PSA and IgG2b-PSA 337 
 In mice, FcγRIV binds monomeric IgG2a and IgG2b. At physiological concentrations of 338 
IgG2a (≈ 2.5 mg/mL) and IgG2b (≈ 1.5 mg/mL) in the serum, FcγRIV may therefore be occupied 339 
in vivo, particularly on circulating neutrophils and monocytes. Nevertheless, the short binding 340 
half-lives of monomeric IgG2a (t1/2 ≈ 3 min) and monomeric IgG2b (t1/2 ≈ 10 min) by FcγRIV, 341 
and their ability to be displaced from this receptor by immune complexes,14 may enable IgG2-342 
immune complexes to interact with FcγRIV during anaphylaxis and therefore contribute to its 343 
induction and/or severity. 344 
 To explore this possibility, we primed FcγRIII-/- mice with various doses of anti-TNP 345 
IgG2a before challenge with TNP-BSA, in order to induce a range of in vivo concentrations of 346 
immune complexes. As expected, the low doses did not trigger FcγRIII-/- mice to develop 347 
anaphylaxis after challenge. Elevated doses (1 or 2 mg), however, enabled significant 348 
temperature drops in FcγRIII-/- mice, comparable to those observed in WT mice primed with 500 349 
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µg IgG2, particularly at the highest dose of IgG2a (2 mg) (Figure 4A). Already at a dose of 1mg 350 
of IgG2, FcγRIII-/- mice developed mild hypothermia in IgG2a-PSA but not in IgG2b-PSA 351 
(Figure 4B&C). Unexpectedly in the same conditions, FcγRIV contributed to IgG2b-PSA that 352 
was not anymore dampened by inhibitory FcγRIIB (Figure 4C). At a dose of 2 mg of IgG, 353 
FcγRIII-/- mice developed hypothermia in both IgG2a-PSA and IgG2b-PSA that was abolished 354 
when FcγRIII-/- mice were pre-treated with a blocking antibody against FcγRIV (Figure 4D&E). 355 
FcγRI did not contribute to either model of IgG2-PSA at an elevated dose (Figure 4B&C). 356 
Furthermore, the expression of FcγRIII was down regulated on neutrophils and basophils, but not 357 
on Ly6Chi monocytes, following IgG2b-PSA (Figure 5A&D). The expression of FcγRIV was 358 
also down regulated on neutrophils, but not on Ly6Clo monocytes (Figure 5B&D). The 359 
expression of FcγRIIB, however, did not change on either neutrophils or Ly6Chi and Ly6Clo 360 
monocytes even though this inhibitory receptor regulates IgG2b-PSA (Figures 1C and 5C&D). 361 
This observation is in agreement with the report by Khodoun et al, reporting that FcγRIIB 362 
expression did not change on neutrophils following IgG1-PSA31. Altogether high doses of 363 
antigen-specific IgG2 reveal the contribution of FcγRIV to IgG2a-PSA and to IgG2b-PSA, and 364 
suggest the direct activation of neutrophils and basophils by IgG2b-immune complexes. 365 
 366 
IgG1 PSA in the absence of inhibitory FcγRIIB  367 
The unexpected differences observed between IgG2a- and IgG2b-PSA induction 368 
pathways prompted us to find a mouse model more sensitive to IgG1-PSA than WT mice, to be 369 
able to evaluate the contribution of cell types and mediators also in this model. Indeed, as 370 
mentioned earlier, WT mice respond poorly to IgG1-PSA (Figure 1A; Supplemental Figure 371 
4A)18. FcγRIIB-/- mice, however, develop a temperature drop of ≈4°C during IgG1-PSA, 372 
comparable to temperature losses observed in WT mice during IgG2a- or IgG2b-PSA (Figure 373 
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1B&C). We therefore analyzed the contribution of cell types to IgG1-PSA in FcγRIIB-/- mice. 374 
Basophil depletion mildly - but significantly - inhibited IgG1-PSA (Figure 6A), in agreement 375 
with previous data19. The depletion of neutrophils had the same effect, although not consistently 376 
as strongly as basophil depletion (Figure 6B and data not shown). Monocyte/macrophage 377 
depletion had only a tendency to ameliorate anaphylaxis that was reproducible but not significant 378 
(Figure 6C). These results suggest that IgG1-PSA relies on basophils and neutrophils, and 379 
possibly also on monocytes. 380 
 381 
PAF and histamine contribute differentially to IgG2a- and IgG2b-PSA 382 
Because cell types contribute differently to IgG2-PSA models (i.e. IgG2a-PSA, 383 
neutrophils and monocytes; IgG2b-PSA, basophils, neutrophils and monocytes), one can expect 384 
that the mediators responsible for clinical signs also may differ between them. Platelet activating 385 
factor (PAF) has been shown to be responsible for anaphylactic reactions that required basophil19, 386 
neutrophil16, 24 and/or monocyte/macrophage22 activation, whereas histamine has been shown to 387 
be responsible for mast cell- and basophil-dependent anaphylaxis35, 36. Neutrophils are the main 388 
producers of PAF37, whereas mast cells and basophils are the main producers of histamine38, 39. 389 
We therefore analyzed the relative contribution of these two mediators to the three models of 390 
PSA using the histamine-receptor 1 antagonist cetirizine and the PAF-R antagonist ABT-491. 391 
Surprisingly, histamine-receptor 1 antagonist cetirizine significantly inhibited IgG1-PSA whereas 392 
PAF-R antagonist ABT-491 had no significant effect, in opposition with previous data19. The 393 
combination of both antagonists had an additive effect, and almost abolished IgG1-PSA (Figure 394 
7A). These results obtained in FcγRIIB-/- mice were confirmed in WT mice (Figure 7A). Whereas 395 
cetirizine mildly reduced hypothermia in IgG2a-PSA, it significantly inhibited IgG2b-PSA. ABT-396 
491 mildly reduced hypothermia in IgG2a-PSA, but had no significant effect on IgG2b-PSA 397 
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(Figure 7B&C). The combination of cetirizine and ABT-491, however, almost abolished both 398 
IgG2a- and IgG2b-PSA. Elevated plasma histamine levels were detected 5 minutes post 399 
challenge in all three IgG-PSA models, and particularly high levels were observed in mice 400 
undergoing IgE-PSA (as a positive control) or undergoing IgG2a-PSA (Figures 7D&E). This 401 
latter finding is surprising as IgG2a-PSA is unaffected by the absence of both mast cells and 402 
basophils that are considered major sources of histamine. Mast cell protease-1 (mMCP-1), which 403 
is released upon activation of mucosal mast cells, could be detected in the serum of mice 404 
undergoing IgE-PSA, but not in those undergoing any one of the three models of IgG-PSA, 3 405 
hours post-PSA induction (Figure 7F). Collectively these results suggest that histamine 406 
predominantly contributes to IgG1- and IgG2b-PSA, whereas histamine and PAF, together, are 407 
necessary for IgG2a-PSA. 408 
 409 
 410 
 411 
  412 
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DISCUSSION 413 
Our work suggests that the activating IgG receptor FcγRIII predominantly contributes to 414 
IgG-dependent passive systemic anaphylaxis, whether induced by IgG1, IgG2a or IgG2b 415 
antibodies. A contribution of the activating IgG receptor FcγRIV was only identified when using 416 
very high amounts of IgG2 antibodies, whereas the activating IgG receptor FcγRI played no 417 
detectable role. Remarkably, the inhibitory IgG receptor FcγRIIB controlled the severity of IgG1- 418 
and IgG2b-, but not IgG2a-induced anaphylaxis. The ability of FcγRIIB to inhibit a given model 419 
of IgG-induced anaphylaxis correlated with the contribution of basophils and histamine to that 420 
model. Indeed, basophils, and possibly mast cells, contributed with neutrophils to IgG1-PSA, and 421 
with neutrophils and monocytes to IgG2b-PSA, but not to IgG2a-PSA that appeared to depend 422 
entirely on neutrophils and monocytes/macrophages. Altogether our data propose that the three 423 
IgG subclasses IgG1, IgG2a and IgG2b induce three qualitatively different pathways of 424 
anaphylaxis that are nevertheless triggered primarily by a single IgG receptor, FcγRIII.  425 
 426 
 FcγRIII is a low-affinity receptor for IgG1, IgG2a and IgG2b, whereas FcγRI is a high-427 
affinity receptor for IgG2a, and FcγRIV is a high affinity receptor for IgG2a and IgG2b. One 428 
would therefore assume that FcγRIII predominates in IgG1-PSA, FcγRI and FcγRIV in IgG2a-429 
PSA, and FcγRIV in IgG2b-PSA. However, our data from FcγRIII-/- mice indicate that this 430 
receptor predominates in all three models. Notably, we found an increased expression of FcγRIIB 431 
on neutrophils and Ly6Chi monocytes in FcγRIII-/- mice, which could mask a potential 432 
contribution of FcγRIV in these conditions. In support of the notion that FcγRIII predominates 433 
IgG-PSA induction, an alternative model of PSA induced by sensitization and challenge with 434 
goat antibodies was found to be driven by FcγRIII22 and blocking antibodies against FcγRIII 435 
were protective in a model of PSA induced by IgG immune complexes16. In addition, IgG2a-PSA 436 
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in FcγRIIB-/- mice was abolished following injection of anti-FcγRIIB/III blocking mAbs5. 437 
FcγRIII is the only activating IgG receptor in the mouse that does not bind an IgG subclass with 438 
high affinity, thus it remains unoccupied by monomeric IgG and accessible for binding of 439 
immune complexes. This is theoretically not the case for FcγRI and FcγRIV, which at 440 
physiological serum concentrations of IgG2a (≈ 2.5 mg/mL) and IgG2b (≈ 1.5 mg/mL), are likely 441 
occupied in vivo, particularly on circulating cells. Of note, C57Bl/6 mice produce IgG2c, but not 442 
IgG2a antibodies, whose amino acid sequence varies by about 15%. Experiments performed in 443 
Balb/c mice that express endogenous IgG2a (but no IgG2c) gave similar results regarding the 444 
contribution of basophils, neutrophils and monocytes to IgG2a (Supplemental Figure 4B), 445 
indicating that IgG2a and IgG2c sequence variations probably do not affect the mechanisms of 446 
anaphylaxis induction that we describe herein. 447 
 Adult female mice of 20 g, as used in this study, possess a circulating blood volume of 448 
1.4-1.5 mL. Injection of 500 µg antibody thus corresponds to ≈330 µg/mL of circulating 449 
antibody, injection of 1 mg to ≈660 µg/mL, and injection of 2 mg to ≈1,3 mg/mL. In cases of 450 
anaphylaxis the circulating concentration of allergen-specific IgG has not been evaluated due to 451 
lack of testing and appropriate controls (i.e. monoclonal anti-allergen antibodies); although we 452 
have reported high circulating antigen-specific IgG levels in an autoimmune model of arthritis33. 453 
It seems rather unlikely that patients suffering from anaphylaxis possess such elevated circulating 454 
levels of IgG anti-allergen as in the mice receiving the high doses we used in this study. 455 
Nevertheless, our results in high-dose IgG2a- and IgG2b-PSA demonstrate that FcγRIV can by 456 
itself (i.e. in the absence of FcγRIII) trigger anaphylaxis. Similar results have been obtained in 457 
mice expressing only FcγRIV: “FcγRIV-only” mice developed IgG2b-PSA after injection of pre-458 
formed IgG2b immune complexes and also upon injection of polyclonal anti-sera followed by a 459 
challenge with the antigen16. We reported previously that IgG2b-PSA triggered by the injection 460 
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of preformed IgG2b-immune complexes in WT mice was abolished following injection of anti-461 
FcγRIV blocking mAb 9E9. This contrasts with the findings of the current study, in which we 462 
show that FcγRIII is the major activating receptor in all models of IgG-PSA, and FcγRIV 463 
contributes only at high antibody concentrations. Two hypotheses may explain these discrepant 464 
results: i) the injection of preformed IgG2b-immune complexes leads to an immediate circulating 465 
bolus of immune complexes, which are similarly formed only after injection of high amounts of 466 
IgG2b and antigen, thus triggering FcγRIV; 2) as recently reported40 mAb 9E9 may not only 467 
block FcγRIV through its Fab portions, but also FcγRIII via its Fc portion once 9E9 is bound to 468 
FcγRIV. In our view, it is likely that a combination of these mechanisms reconcile our previous 469 
and herein described results, and suggest that IgG2b-PSA induced following injection of 470 
preformed IgG2b-immune complexes relies rather on both FcγRIII and FcγRIV than on FcγRIV 471 
alone as we reported previously16. Together this body of evidence supports the notion that 472 
FcγRIV is capable of triggering cell activation leading to anaphylaxis, yet in restricted conditions, 473 
i.e. in the absence/blockade of FcγRIII or in presence of large amounts of IgG2a and/or IgG2b 474 
antibodies. 475 
 476 
 The differential contribution of FcγRs to IgG-PSA may rely on their respective expression 477 
patterns on myeloid cells. Indeed, FcγRI is not32, 33 or only barely34 expressed on circulating 478 
monocytes, and its expression is largely restricted to tissue-resident macrophages. The level of its 479 
expression on cells reported to contribute to anaphylaxis (i.e. monocytes in this case) may 480 
therefore not suffice to induce their activation. This notion is supported by the absence of any 481 
detectable effect of FcγRI deficiency in IgG2-PSA that we report in this study, even at high doses 482 
of IgG2 antibodies. FcγRIII, however, is expressed on all myeloid cells7 and moreover at 483 
comparably high levels on all those cell types that have been reported to contribute to 484 
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anaphylaxis; basophils, monocytes and neutrophils20. This pattern of cellular expression may 485 
explain its predominant contribution to all models of IgG-induced anaphylaxis. FcγRIV is 486 
expressed on neutrophils and Ly6Clo monocytes. It remains unclear, however, if Ly6Clo, Ly6Chi 487 
or both monocyte subsets contribute to anaphylaxis. FcγRIV could contribute to PSA induction in 488 
exceptional conditions (FcγRIII deficiency or high IgG2 antibody doses). The lack of FcγRIV 489 
contribution in classical conditions of PSA may suggest that its expression level is not sufficient 490 
in WT mice. Notably, it has been reported previously that particular FcγR deficiencies modify the 491 
expression levels of other FcγRs. In particular FcγRIII-/- mice, but not FcγRI-/- mice, presented a 492 
significant increase in FcγRIV expression levels on neutrophils16, 41, 42 and a tendency for 493 
increased expression on Ly6Clo monocytes (Supplemental Figure 5B). This could explain why 494 
the contribution of FcγRIV to IgG2-PSA becomes apparent in FcγRIII-/- mice. FcγRIV-/- mice did 495 
not, conversely, present alterations of FcγRIII expression on neutrophils or Ly6Chi monocytes 496 
compared to WT littermates (Supplemental Figure 5A). FcγRIIB-/- mice expressed significantly 497 
higher levels of FcγRIII and FcγRIV on neutrophils and increased FcγRIII on Ly6Chi monocytes 498 
that may, altogether, contribute to their higher susceptibility to anaphylaxis induction 499 
(Supplemental Figure 5A&B). 500 
 501 
 The contribution of a rather restricted subset of myeloid cells to these (and other) models 502 
of anaphylaxis2, 3 appears to be determined by at least two factors: their capacity to release 503 
anaphylactogenic mediators (e.g. histamine or PAF) and their expression of sufficient levels of 504 
activating IgG receptors. Mast cells and basophils release histamine, and neutrophils, monocytes/ 505 
macrophages and basophils release PAF, upon FcγR-triggering. Other mediators may induce 506 
anaphylaxis or contribute to its severity, among them lipid mediators like prostaglandins, 507 
thromboxanes and leukotrienes. Some of these have indeed been reported to trigger 508 
                                                                                                                                       Beutier 
 
 
24 
bronchoconstriction and an increase in vascular permeability43. The release of such mediators is 509 
sufficiently rapid to coincide with the celerity of hypothermia, which is detectable within minutes 510 
after allergen challenge. It is therefore surprising that eosinophils do not contribute to IgG-PSA, 511 
as they express high levels of activating FcγRIII and FcγRIIB20 (but no FcγRI or FcγRIV), and 512 
are capable of releasing Leukotriene C4, Prostaglandin E2, thromboxane and PAF upon 513 
activation43. Though eosinophils represent relatively low numbers among blood cells 514 
(≈2x105/mL), this is an unlikely explanation because basophils are significantly less numerous 515 
(≈5x104/mL) but do contribute to anaphylaxis models. Most revealingly, it has been reported that 516 
eosinophils do not release PAF following IgG-dependent activation44. Whether eosinophils 517 
produce other potentially anaphylactogenic mediators following IgG-immune complex activation 518 
has not been investigated, but the lack of such an effect appears the most reasonable hypothesis 519 
to explain why eosinophils have not been found to contribute to IgG-induced anaphylaxis. 520 
We investigated the contribution of neutrophils and monocytes to IgG-PSA models using 521 
depletion approaches. Ly6G+ cell depletion using NIMP-R14 resulted in an efficient depletion of 522 
neutrophils in the blood and the spleen (Supplemental Figures 1B&2B). The same treatment 523 
resulted only in a partial depletion in the bone marrow, in which a proportion of Ly6G+ cells are 524 
masked from fluorescent anti-Ly6G staining, but not depleted by NIMP-R14 treatment (refer to 525 
bone marrow panels in Supplemental Figures 1C,D & 2C,D,I). Importantly, we found that NIMP-526 
R14 depletion has a significant impact on monocyte populations in the blood and to some extent 527 
in the spleen. This should be taken into consideration when interpreting the results of NIMP-R14 528 
depletion experiments. All IgG-PSA models were ameliorated following NIMP-R14 depletion, 529 
but also when monocytes/macrophages were targeted using clodronate liposomes. Intravenous 530 
injection of clodronate liposomes resulted in a significant depletion of monocytes from the blood 531 
and monocytes/macrophages from the spleen and BM, but not from the skin (data not shown) and 532 
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peritoneum (Supplemental Figures 1&2, as reported26), and to a significant increase in blood 533 
leukocyte counts and particularly of neutrophils (Supplemental Figures 1&2). Thus the anti-534 
Ly6G and the clodronate liposome treatments alter also the monocytes and neutrophil 535 
compartment, respectively, but reduced hypothermia in the three models of IgG-PSA studied. 536 
Constitutive deficiency in neutrophils, studied using Gfi1-/- mice, confirmed the role of 537 
neutrophils in IgG2a- and IgG2b-PSA models. Both neutrophils and monocytes can therefore be 538 
considered to contribute to IgG-induced anaphylaxis in mice, whether dependent on IgG1, IgG2a 539 
or IgG2b. The role of macrophages in the different IgG-PSA models remains to be investigated 540 
more deeply, as clodronate liposomes injected intravenously efficiently targeted macrophages in 541 
the spleen, but not in other tissues like peritoneum or skin, and thus do not allow conclusions on 542 
their contribution.   543 
 544 
 The contribution of basophils to models of anaphylaxis has been a recent matter of 545 
debate. Tsujimura et al reported that depletion of basophils using anti-CD200R3 (clone Ba103) 546 
monoclonal antibodies strongly inhibited IgG1-PSA and rescued mast cell-deficient mice from 547 
active anaphylaxis19. Ohnmacht et al, however, found that basophil-deficient Mcpt8cre mice 548 
demonstrated slightly decreased but significant hypothermia in response to IgG1-PSA (induced 549 
with the same antibody clone) when compared to WT mice45. More recently, Reber et al. 550 
reported that peanut-induced anaphylaxis was reduced following Diphtheria toxin injection in 551 
Mcpt8DTR mice that selectively depletes basophils, and confirmed that basophil depletion using 552 
anti-CD200R3 mAbs inhibited anaphylaxis36. Moreover, Khodoun et al found a contribution of 553 
basophils to anaphylaxis mortality, but not to hypothermia, in a model of IgG2a-PSA following 554 
anti-CD200R3 mAb injection5. It therefore appears that differences between inducible basophil 555 
depletion using specific antibodies or toxin administration and a constitutive lack of basophils, 556 
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possibly leading to compensatory mechanisms during development of these mice, may account 557 
for the divergent results observed. Intriguingly however, basophils have been reported to be 558 
resistant to IgG-immune complex triggering ex vivo due to dominant inhibition by FcγRIIB over 559 
activation by FcγRIII20. In this study, we report that both basophil depletion following anti-560 
CD200R3 mAb (Ba103) injection or constitutive deficiency of basophils and mast cells in Cpa3-561 
Cre; Mcl-1fl/fl mice inhibits IgG2b-PSA but not IgG2a-PSA, confirming a role for basophils (and 562 
potentially mast cells) to specific IgG-PSA models. Of note, Ba103 efficiently depleted basophils 563 
from the blood and partially from the spleen and the bone marrow, but had no significant effect 564 
on mast cells in the peritoneum or skin (Supplemental Figures 1A&1E and 2A&2E). The 565 
difference in the ability of basophils to respond to IgG-immune complex triggering in vitro and 566 
the various in vivo models may be explained by functional alterations during basophil purification 567 
or a requirement for co-stimulation by other cells or their products that are present in vivo, but not 568 
ex vivo, for basophils to respond to IgG-immune complexes. Our results using Cpa3-Cre; Mcl-569 
1fl/fl mice indicate that mast cells were not necessary for IgG2a-PSA. We could not formally 570 
define their role in IgG2b-PSA as basophil depletion and deficiency in basophils and mast cells 571 
lead to similar reduction in IgG2b-PSA. Notably, increased plasma histamine levels, but no 572 
increase in mMCP-1 levels could be detected, suggesting that mucosal mast cells were not 573 
activated during IgG-PSA. Intriguingly, however, dermal mast cells displayed a degranulated 574 
morphology 30 minutes after challenge in all IgG PSA models tested (Supplemental Figure 7). 575 
Whether their degranulation is a cause or a consequence of anaphylaxis remains however elusive. 576 
 577 
 The ability of cells expressing activating FcγRs to respond to IgG-immune complexes has 578 
been proposed to be regulated by co-expression of FcγRIIB46. FcγRIIB-/- mice develop increased 579 
hypersensitivity and anaphylactic reactions to IgG1-PSA (this report and16, 18). Our results further 580 
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demonstrate that FcγRIIB inhibits IgG2b-, but not IgG2a-PSA. This latter finding is supported by 581 
results from Khodoun et al5: these authors proposed that the lack of this inhibitory receptor may 582 
lead to increased spontaneous formation of immune complexes in FcγRIIB-/- mice, that could 583 
compete with IgG2a-immune complexes. In light of our results comparing IgG1-, IgG2a- and 584 
IgG2b-PSA, we rather propose that the significantly lower affinity of inhibitory FcγRIIB for 585 
IgG2a (KA = 4.2 105 M-1) than for IgG1 (KA = 3.3 106 M-1) and IgG2b (KA = 2.2 106 M-1) is the 586 
determining factor (Table 1). Another factor may be the variance in expression of FcγRIIB on 587 
circulating myeloid cells: basophils > monocytes > eosinophils >> neutrophils20. Whereas the 588 
exact numbers of expressed activating FcγRIII and inhibitory FcγRIIB per cell remain unknown, 589 
flow cytometric analysis allowed the estimation of their relative expression: indeed, the ratio 590 
FcγRIII/FcγRIIB is higher on neutrophils than on monocytes and basophils. These differential 591 
expression levels may thus explain why neutrophils contribute to anaphylaxis, as the receptor 592 
balance is in favor of the activating receptor. Strikingly, FcγRIIB is co-expressed only with 593 
FcγRIII on basophils and Ly6Chi monocytes, whereas it is co-expressed with FcγRIII and FcγRIV 594 
on neutrophils and Ly6Clo monocytes34. Contribution of a given cell type to anaphylaxis may 595 
therefore be favored when inhibitory FcγRIIB is required to dampen the stimulatory potential of 596 
two activating IgG receptors instead of one. This concept extends to IgG1-immune complexes 597 
that only engage one activating receptor, FcγRIII. 598 
 599 
 Our results on the contribution of mouse IgG receptors, cells and mediators in IgG-600 
induced anaphylaxis can potentially be translated to human IgG-mediated anaphylaxis, e.g. 601 
following intravenous IgG or therapeutic IgG antibody administration. Indeed, even though IgG 602 
receptors are different in the two species, we have already reported that human FcγRI (hFcγRI) 603 
and human FcγRIIA (hFcγRIIA) can induce anaphylaxis when expressed under the control of 604 
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their own promoter in transgenic mice23, 24. hFcγRI (CD64) is the equivalent of mouse FcγRI 605 
whereas hFcγRIIA (CD32A) can be regarded as the equivalent of mouse FcγRIII, and hFcγRIIIA 606 
(CD16A) the equivalent of mouse FcγRIV7. hFcγRIIA, like mouse FcγRIII, is expressed on all 607 
myeloid cells and could therefore act as the principal IgG receptor responsible for anaphylaxis in 608 
humans. hFcγRIIB, the equivalent of mouse FcγRIIB, is scarcely expressed on most circulating 609 
myeloid cells47 except for its high expression on basophils20, suggesting that among myeloid cells 610 
only human basophils are highly sensitive to hFcγRIIB-mediated inhibition. In contrast to mouse 611 
FcγRI, hFcγRI is constitutively expressed on circulating monocytes and inducibly on neutrophils, 612 
allowing this receptor to induce anaphylaxis24. The binding of human IgG subclasses to hFcγRs 613 
differs strikingly from the binding of mouse IgG subclasses to mouse FcγRs. Noticeably, the 614 
affinity of hFcγRIIB for any human IgG subclass is the lowest among human IgG-hFcγR 615 
interactions. For example, human IgG1, the equivalent of mouse IgG2a, is bound by all activating 616 
hFcγRs (KA > 106 M-1) with at least a ten-fold higher affinity than by inhibitory hFcγRIIB (KA ≈ 617 
105 M-1)48. If we consider the translation of our results obtained in the mouse to human IgG-618 
induced anaphylaxis, one could anticipate that hFcγRIIB-mediated inhibition of IgG-induced 619 
anaphylaxis is inefficient in human neutrophils and monocytes, and efficient only in human 620 
basophils for which the elevated hFcγRIIB expression may compensate for the low-affinity of 621 
this receptor for human IgG subclasses. Certainly, FcγR-engagement by IgG immune complexes 622 
on human basophils could not trigger any detectable basophil activation in vitro20, similar to the 623 
results we reported for mouse basophil activation. Our data altogether propose that the 624 
differential expression of inhibitory FcγRIIB on myeloid cells and its differential binding of IgG 625 
subclasses control the contribution of basophils, neutrophils and monocytes to IgG-dependent 626 
anaphylaxis, thus revealing novel complexities in the mechanism of regulation of cell 627 
populations, and therefore their contribution to IgG-mediated reactions in vivo.  628 
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TABLES 790 
 791 
Table 1: Affinities of mouse FcγR-IgG subclass interactions (KA values in M-1) 792 
 793 
 IgG1 IgG2a IgG2b IgG3 
FcγRI - 1x108 1x105 (+) 
FcγRIIB 3.3x106 4.2x105 2.2x106 - 
FcγRIII 3.1x105 6.8x105 6.4x105 - 
FcγRIV - 2.9x107 1.7x107 - 
“-”, no detectable affinity. 794 
“(+)”, under debate11, 12. 795 
Data compiled from 17, 21 796 
 797 
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FIGURE LEGENDS 799 
 800 
Figure 1. FcγRIII dominates in IgG-PSA models. Mice injected with anti-TNP mAbs were 801 
challenged with TNP-BSA and body temperatures monitored. (A) IgG1-, (B) IgG2a- or (C) 802 
IgG2b-induced PSA in indicated mice (n≥3/group). Data are representative of at least two 803 
independent experiments (A: n=2; B: n=3; C: n=2). Significant differences compared to the WT 804 
group are indicated. 805 
 806 
Figure 2. Basophils, mast cells, monocytes/macrophages and neutrophils contribute 807 
differentially to IgG-PSA models. Indicated mice (n≥8/group) were injected with IgG2a (A-E) 808 
or IgG2b (F-J) anti-TNP mAbs, challenged with TNP-BSA and body temperatures were 809 
monitored. WT mice (n=8/group) were pretreated as indicated (A, C-D, F, H-I). Lipo-PBS: PBS 810 
liposomes; Lipo-Cd: clodronate liposomes. Data are pooled from at least two independent 811 
experiments. 812 
 813 
Figure 3. Reduced expression of FcγRIII and FcγRIV, but not FcγRIIB, on neutrophils 814 
following IgG2a-PSA. (A) FcγRIII, (B) FcγRIV and (C) FcγRIIB expression on blood cells from 815 
WT mice (A&B: n=11/group; C: n≥6/group) left untreated, injected with IgG2a anti-TNP mAbs, 816 
or injected with IgG2a anti-TNP mAbs and challenged with TNP-BSA. (D) Compilation of Δ 817 
Geomean +/- SEM data from A-C. 818 
 819 
Figure 4. High doses of IgG2 antibodies reveal FcγRIV contribution to IgG2-PSA. (A) PSA 820 
in indicated mice injected with various doses of IgG2a anti-TNP mAbs (n=2/group). (B-E) PSA 821 
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in indicated mice (B&C: n=8/group; D&E: n≥3/group) injected with indicated doses of anti-TNP 822 
mAbs. Data are pooled from two independent experiments. Significant differences compared to 823 
the untreated WT group are indicated. 824 
 825 
Figure 5. Expression of FcγRs on myeloid cells following IgG2b-PSA. (A) FcγRIII (left: 826 
n=8/group, right: n=3/group), (B) FcγRIV (n=8/group) and (C) FcγRIIB expression (n≥6/group) 827 
on cells from WT mice (n=8/group) left untreated, injected with IgG2b anti-TNP mAbs, or 828 
injected with IgG2b anti-TNP mAbs and challenged with TNP-BSA. (D) Compilation of Δ 829 
Geomean +/- SEM data from A-C. 830 
 831 
Figure 6. Cell contributions to IgG1-PSA in the absence of inhibitory FcγRIIB. FcγRIIB-/- 832 
mice were pretreated as indicated, then injected with IgG1 anti-TNP mAbs, challenged with 833 
TNP-BSA and central temperatures were monitored (A: n=8/group; B: n=7/group; C: 834 
n=10/group). Data are represented as mean +/- SEM. Data are pooled from two independent 835 
experiments. 836 
 837 
Figure 7. Contributions of histamine and PAF to IgG-PSA. Body temperatures of pretreated 838 
mice during (A) IgG1-PSA in FcγRIIB-/- (n=6/group) or WT mice (n=4/group), (B) IgG2a-PSA, 839 
(C) IgG2b-PSA or (D) IgE-PSA in WT mice (n≥7/group). (E) Histamine and (F) mMCP-1 840 
concentrations post-PSA (n=3/group). Data are representative of at least two independent 841 
experiments, except for A&C (pooled from two independent experiments). 842 
  843 
  844 
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Supplemental Figure 1. Effects of depletion strategies on myeloid cell populations – Cell 1 
counts. WT mice were treated with indicated reagents. 24 hours after injection, counts of specific 2 
cell populations were determined by flow cytometry (A-G) or histology (I&J); leukocyte counts 3 
in total blood were measured with an automatic blood analyzer (H). Counts of (A) basophils, (B) 4 
neutrophils, (C) Ly6Chi monocytes and (D) Ly6Clo monocytes in blood, spleen and bone marrow, 5 
(E) peritoneal mast cells (F) peritoneal macrophages and (G) splenic macrophages. (I) 6 
Representation of a toluidine blue-stained back skin section with two mast cells (arrows). (J) 7 
Counts of mast cells/mm2 in the dermis of WT mice. (A-H) Figures show one of three 8 
independent experiments. Individual measurements and mean +/- SEM are represented. Iso = 9 
isotype rat IgG2b, Ba103 = anti-CD200R3 mAb, NIMP = anti-Ly6G mAb, PBS = PBS 10 
liposomes, CS= clodronate liposomes. 11 
 12 
Supplemental Figure 2. Effects of depletion strategies on myeloid cell populations – 13 
Frequencies. WT mice were treated with indicated reagents. 24 hours after injection, percentages 14 
of specific cell populations among CD45+ cells were determined by flow cytometry (A-H): (A) 15 
basophils, (B) neutrophils, (C) Ly6Chi monocytes and (D) Ly6Clo monocytes in blood, spleen and 16 
bone marrow, (E) peritoneal mast cells (F) peritoneal macrophages and (G) splenic macrophages. 17 
(H) Percentages of peritoneal mast cells (pMC FcεRI+/cKit+) and blood basophils (FcεRI+/DX5+) 18 
in Cpa3-Cre; Mcl-1fl/fl mice and in Cpa3-Cre; Mcl-1+/+ mice. (I) Left: Percentages of YFP-19 
positive cells in MRP8-Cre; Rosa26-YFP mice. Right: Effect of NIMP-R14 injection on 20 
neutrophils (percentages and counts CD45+/YFP+/Ly6Cneg/CD115neg cells) in blood, spleen and 21 
bone marrow of MRP8-Cre; Rosa26-YFP mice. (A-H) Figures show corresponding percentages 22 
to cell counts shown in Supplemental Figure 1 and display values for individually measured mice 23 
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2 
and the mean and SEM. Iso = isotype rat IgG2b, PBS = PBS liposomes, CS= clodronate 24 
liposomes. 25 
 26 
Supplemental Figure 3. Relative affinity of IgG1 (TIB191), IgG2a (Hy1.2) and IgG2b 27 
(GORK) anti-TNP to TNP-BSA. (A) ELISA anti-TNP. Comparison of binding capacity of 28 
TIB 191, Hy1.2 or GORK to immobilized TNP-BSA. Data are represented as mean +/- SEM and 29 
representative of results from five independent experiments. (B) Surface plasmon resonance 30 
analysis. Comparison of binding affinity TNP-BSA to immobilized TIB 191, Hy1.2 or GORK 31 
clones. (C) The table recapitulates the kon, koff and Kd for each condition. 32 
 33 
Supplemental Figure 4. IgG1-PSA induces mild hypothermia in WT mice and 34 
monocytes/macrophages and neutrophils contribute to IgG2a-PSA in Balb/c mice. (A) WT 35 
mice were injected with IgG1 anti-TNP mAbs, challenged with TNP-BSA and body temperatures 36 
were monitored. PSA in mice left untreated, injected with anti-Ly6G or anti-CD200R3 37 
(n=4/group). (B) Balb/c mice were left untreated, injected with anti-Ly6G, anti-CD200R3 38 
(n=6/group), lipo-PBS (n=6/group) or lipo-Cd (n=6/group) prior to IgG2a-PSA induction. Body 39 
temperatures were monitored. Data are represented as mean +/- SEM. Data are pooled from two 40 
independent experiments. Significant differences compared to the untreated group are indicated. 41 
 42 
Supplemental Figure 5. FcγR expression in FcγR-deficient mice. Expression of (A) FcγRIII,  43 
(B) FcγRIV and (C) FcγRIIB is represented as the ΔGeomean of FcγR-specific staining 44 
compared to isotype control staining from blood leukocytes collected from untreated WT, FcγRI-45 
/-, FcγRIIB-/-, FcγRIII-/- and FcγRIV-/- mice (n=4/group). Data are represented as mean +/- SEM.  46 
 47 
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3 
Supplemental Figure 6. Blood leukocyte numbers in FcγR-deficient mice. Leukocyte 48 
populations were assessed using an ABC Vet automatic blood analyzer (Horiba ABX) from 49 
blood collected from untreated WT, FcγRI-/-, FcγRIIB-/-, FcγRIII-/- and FcγRIV-/- mice 50 
(n=4/group). “Granulocytes” represent mainly neutrophils (as judged by their size and 51 
granularity). Data are represented as mean +/- SEM; each point represents one mouse.  52 
 53 
Supplemental Figure 7. Mast cell degranulation after IgG1, IgG2a and IgG2b-induced PSA. 54 
WT mice were injected with IgE, IgG1, IgG2a, IgG2b anti-TNP mAbs or left untreated (n=3 for 55 
all groups) and challenged with TNP-BSA. Mouse ear skin biopsies were collected 30 minutes 56 
after TNP-BSA injection. Representation of a toluidine blue-stained ear skin sections with one 57 
mast cell (indicated by an arrow) for one mouse of each group of mice. 58 
 59 
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